APEIRON Biologic's work on a drug candidate against COVID-19
Read more
Improving the life of our patients with next-generation technologies and individual therapies About UsContact Us Improving the life of our patients with next-generation technologies and individual therapies About UsContact Us

APEIRON Biologics at a glance

  • First Austrian biotech company to develop a cancer immunotherapy product through to market
  • Approval in 2017 for treatment of pediatric neuroblastoma in EU and other countries, US/Japan BLA filing in preparation
  • Respiratory drug candidate APN01 in clinical development
  • Oncology pipeline in clinical stages
  • Focused on novel cancer immunotherapies and respiratory treatments
  • Lead by highly experienced and motivated team with global background

NEWS

APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery
- Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431 - Inhibitors discovered at Domainex via virtual and fragment screening Press release (EN) | Presseaussendung (DE)
November 9, 2020
APEIRON Biologics AG strengthens shareholder structure and Supervisory Board with international anchor investor
- British investor consortium Franklin Road Ltd. increases its stake in APEIRON Biologics significantly to over 13% - Extraordinary General Meeting elects Edward Charles MA, Managing Director of Franklin Road Ltd., as a new Supervisory Board member Press release (EN) | Presseaussendung (DE)
October 15, 2020
THE LANCET publishes promising data of APEIRON’s APN01 (rhsACE2) to treat COVID-19 in named patient use
- Case study from promising first COVID-19 patient treatment with APN01 supports APEIRON’s ongoing pivotal Phase II clinical trial - First data on the effect of blocking the spike protein in COVID-19 patient confirm mode of action of APN01 specifically targeting SARS-CoV-2 Press release (EN) | Presseaussendung (DE)
September 25, 2020